Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anna-Sophie Weik"'
Autor:
Nina Struve, Konstantin Hoffer, Anna-Sophie Weik, Britta Riepen, Leonie Krug, Meryem H Cetin, Jasmin Burmester, Leonie Ott, Jana Liebing, Fruzsina Gatzemeier, Justus Müller-Goebel, Mirja Gerbach, Lara Bußmann, Ann Christin Parplys, Kristian Unger, Wael Y Mansour, Ulrich Schüller, Thorsten Rieckmann, Cordula Petersen, Kai Rothkamm, Susan C Short, Malte Kriegs
Publikováno v:
Neurooncol. Adv. 4:vdab180 (2022)
Background The oncogene epidermal growth factor receptor variant III (EGFRvIII) is expressed in approximately one-third of all glioblastomas (GBMs). So far it is not clear if EGFRvIII expression induces replication stress in GBM cells, which might se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e69c52c55ee3d56cf047f8b71986c1e
https://doi.org/10.1093/noajnl/vdab180
https://doi.org/10.1093/noajnl/vdab180
Autor:
Zev A. Binder, Marvin Henze, Claire Faulkner, Leonie Ott, Ulrich Schüller, Jennifer J.D. Morrissette, Susan C Short, Lara Bußmann, Stephen J Bagley, Konstantin Hoffer, Donald M O Rourke, Thorsten Rieckmann, Lucy F. Stead, Malte Kriegs, Kai Rothkamm, Leonie Krug, Cordula Petersen, Kathreena M Kurian, Anna-Sophie Weik, Tim Brend, Justus Müller-Goebel, Nina Struve
Publikováno v:
Oncogene
The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in glioblastomas (GBM) but its impact on therapy response is still under controversial debate. Here we wanted to test if EGFRvIII influences the sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a69b8243d33e19b7c68217d745061e1
Autor:
Zev A. Binder, Marvin Henze, Stephen J Bagley, Lucy F. Stead, Tim Brend, Nina Struve, Konstantin Hoffer, Thorsten Rieckmann, Claire Faulkner, Anna-Sophie Weik, Ulrich Schüller, Susan C Short, Jasmin Burmester, Leonie Ott, Ann Christin Parplys, Cordula Petersen, Malte Kriegs, Kathreena M Kurian, Kai Rothkamm, Justus Müller-Goebel, Jennifer J.D. Morrissette
Publikováno v:
Neuro Oncol
MGMT promoter methylation is the only accepted biomarker with prognostic role in GBM but its routine implementation is limited partly response to TMZ is heterogeneous, but also due to lack of effective alternative treatment options. Therefore, additi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bcb41bbdc8267b85159c1536b40c257
https://europepmc.org/articles/PMC6847190/
https://europepmc.org/articles/PMC6847190/